Objectives: The response of anthrax lethal toxin (LeTx) induced shock and lethality to conventional therapies has received little study. Previously, fluids worsened outcome in LeTx-challenged rats in contrast to its benefit with lipopolysaccharide (LPS) or Escherichia coli. The current study investigated norepinephrine treatment.
B acillus anthracis lethal toxin (LeTx) consists of protective antigen, necessary for the uptake of toxin by host cells, and lethal factor (LF), the toxic moiety. LeTx is closely associated with the shock and lethality that occurs during anthrax infection (1, 2) . Purified LeTx decreases blood pressure and survival in animal models, and strains of B. anthracis in which protective antigen or LF have been inactivated are 1000 times less lethal than fully active strains (3) (4) (5) . Finally, agents that directly inhibit protective antigen or LF are protective in anthrax models (6 -8) .
Despite the importance of LeTx, the mechanisms underlying the shock and lethality it produces are unclear. LF is a zinc protease that inactivates mitogenactivated protein kinase kinases 1-4, 6, and 7, thereby inhibiting downstream mitogen-activated protein kinases, such as extracellular-signal-regulated kinase 1 or 2, P38, and c-Jun N-terminal kinase (9 -12) . Consistent with its inhibitory effects on these stress kinase pathways, LeTx has not been associated with the excessive inflammatory cytokine and nitric oxide (NO) release that contribute to shock caused by other bacterial toxins (13) . However, LeTx can produce direct endothelial cell apoptosis and increase endothelial permeability (14 -16) . Such endothelial dysfunction with LeTx could lead to shock through the extravasation of intravascular fluid (17) . The hemoconcentration noted in patients with anthrax and in animals challenged with LeTx supports this possibility (13, 18) . Alternatively, however, endothelial dysfunction caused by LeTx could inhibit the response of the systemic vasculature to either endogenous or exogenous catecholamine, or other vasoregulatory molecules. Finally, LeTx could produce direct cellular and tissue injury leading to lethality through mechanisms independent of its effects on hemodynamic function.
Whatever its mechanisms, how LeTxinduced shock responds to conventional hemodynamic support has received little investigation. This question seems important clinically. During the 2001 anthrax outbreak, the uniform fatality in patients with shock despite aggressive hemodynamic support, as well as the pronounced hemoconcentration and recurrent pleural effusions, have suggested that both the pathophysiology and response to treatment with this infection may differ from more common types of sepsis. Using a rat model in which LeTx was infused over 24 hours to simulate its release during infection, we found that normal saline treatment actually decreased blood pressure and survival in patterns different from its effects with lipopolysaccharide (LPS) or Escherichia coli challenge (19) . The adverse effect of fluid with LeTx seemed to be related in part to worsened oxygenation. Further-more, fluid treatment negated the otherwise highly beneficial effects of a protective antigen-directed monoclonal antibody tested in the model. The purpose of the present investigation was to test the influence of norepinephrine, another conventional hemodynamic therapy, on shock and lethality caused by LeTx. We hypothesized that norepinephrine compared with no treatment would increase blood pressure and improve survival with LeTx challenge.
MATERIALS AND METHODS
Animal Care. The protocol used in this study was approved by the Animal Care and Use Committee of the Clinical Center of the National Institutes of Health.
Study Design. Sprague-Dawley rats (n ϭ 195) weighing between 230 and 250 g, with central venous and systemic arterial catheters were briefly anesthetized with isoflurane for connection to infusion lines and transducers. They were then awakened and challenged with either LeTx [LF 150 g/kg with protective antigen 300 g/kg in 12 mL phosphatebuffered saline with rat albumin (25 g/mL)] or E. coli LPS (E. coli 0111:B4, Sigma, 8 mg/kg bw, St. Louis, MO) as 24-hour infusions at a rate of 0.5 mL/hr (6) ( Fig. 1A) . After 1 hour of challenge, 24-hour infusions with low, intermediate, or high doses of norepinephrine (Ben Venue Laboratories, Inc., Bedford, OH) (0.03, 0.3, or 3 g/kg/min) or dextrose 5% diluent (placebo) were started at a rate of 0.5 mL/hr. Animals received similar volumes of toxin and treatment (i.e., 2.0 -2.3 mL/kg/hr for the first hour, 4.0 -4.3 mL/kg/hr for the next 23 hours, and then 2.0 -2.3 mL/kg/h for the final hour). Thus, fluid administration during this period consisted of equal parts of phosphate-buffered saline and dextrose 5%. Immediately before LeTx or LPS and at 2-h intervals, until death or catheter disconnection (24 hours), mean arterial blood pressures (MBP) and heart rates (HR) were recorded. Furthermore, at 4, 8, and 24 hours, arterial blood gas and complete blood counts were measured in animals. All animals had similar volumes (0.5 mL) of blood removed and normal saline replaced with procedures. Animals were observed for 168 hours. To determine the effects of LPS and LeTx alone, measures from Sprague-Dawley rats challenged with diluent (phosphate-buffered saline) in the present (n ϭ 3) and concurrent studies (n ϭ 34) were used together as a control group. These concurrent studies were part of the same ap-proved protocol to investigate hemodynamic support with LeTx and LPS (20) . Care and study of all control animals, including the total fluid volumes administered, were the same as in animals challenged with LeTx or LPS. Animals were observed q2h for the first 24 hours, then q4h from 24 to 48 hours, and q 12h for the remainder of the study and had access to water and feed throughout.
Additional animals (n ϭ 59) in the current study were challenged with LeTx, LPS, or diluent as outlined earlier and then randomly selected at 4 or 8 hours to first be anesthetized for plasma catecholamine, superoxide dismutase (SOD), NO, and cytokine measures, and then killed for lung and liver SOD measurements ( Fig. 1B) . Protective antigen, LF, and LPS for all experiments were prepared as previously described (13, 21, 22) .
Hemodynamic, Blood, and Tissue Measurements. Hemodynamic, arterial blood gas, lactate, norepinephrine, epinephrine, NO, and cytokine measures were performed as previously published (6, 13, 16, 23) . Briefly, arterial blood gases and lactates were measured with iSTAT Clinical Analyzer (Abbott, East Windsor, NJ). Plasma norepinephrine and epinephrine levels were measured using HPLC with electrochemical detection (Bedford, MA). Plasma NO levels were measured with the Cayman Nitrite/nitrate (NO) Colorimetric Kit (Cayman Chemical, Ann Arbor, MI). The serum cytokines tumor necrosis factor-alpha, interleukin (IL)-1␣ and ␤, IL-2, IL-4, IL-6, IL-10, IFN␥, granulocyte-macrophage colonystimulating factor, three migratory inhibitory proteins (MIP-1␣, MIP-2, and MIP-3␣), monocyte chemoattractant protein-1, and regulated on activation, normal T-cell expressed and secreted were measured using a multiplexed sandwich enzyme-linked immunosorbent assay (The SearchLight Rat Cytokine Array, Pierce, Rockford, IL). Total SOD activities in serum, lung, and liver (Cu/Zn-, Mn-, and Fe-SOD) were measured by quantification of the dismutation of superoxide radicals generated by the combination of xanthine oxidase and hypoxanthine (Cayman Chemical Superoxide Dismutase Assay kit, Cayman Chemical, Ann Arbor, MI).
Statistical Analysis. Weekly experiments, including 24 animals each, were performed in which a toxin and treatment combination were assigned using numbers selected randomly. The experiments were designed to detect a 50% reduction in mortality with toxin doses producing an 80% lethality rate. To have 80% power to detect such a difference with an ␣ ϭ 0.05 using a two-tailed test, we estimated that 27 animals would be required per group. However, it was evident after initial cycles that the low and high doses of norepinephrine were having negligible or harmful effects on blood pressure and outcome, and it was not justified to expend further animals studying these doses. Kaplan-Meier survival curves were compared using Gehan's version of the Wilcoxon test, as has been reported previously (24). All other parameters were analyzed with repeated-measures analysis of variance using PROC MIXED in Statistical Analysis System Version 9.1 software (SAS Institute, Cary, NC), and least squares means and associated standard errors were reported. Our interest was focused on the overall group difference and its possible interaction with time. We were not interested in the factor of time, the repeated measure. Similar to earlier studies in this model, MBP and HR data were analyzed during the early period before lethality was evident (i.e., the initial 6 hours in this study) with LeTx (the primary challenge of interest) and then over the later period of observation (8 -24 hours) (20) . p Values were adjusted by the Bonferroni method for the multiple comparisons arising from this early-late dichotomy. Although evaluations of multiple physiologic parameters were performed, no other adjustments to the p values were made. Data were log transformed where appropriate. All results are expressed as least square means Ϯ SEM, and two-sided p Յ 0.05 was considered significant.
RESULTS
Survival. The doses of LPS and LeTx infused resulted in similar lethality rates ( Fig. 2 ). With LPS challenge, the intermediate norepinephrine dose (0.3 g/kg/ min) was beneficial and significantly increased the survival (p ϭ 0.04) ( Fig. 2) . Lowering or increasing the norepinephrine dose (0.03 and 3.0 g/kg/min) with LPS was not associated with beneficial effects. In contrast to LPS, however, with anthrax LeTx challenge neither the intermediate norepinephrine dose nor the higher or lower doses improved survival. Since the intermediate norepinephrine dose (0.3 g/kg/min) but not low (0.03 g/kg/min) or high (3.0 g/kg/min) doses altered survival (i.e., with LPS), analysis is presented for all other laboratory parameters comparing the effects of this intermediate dose alone with LPS vs. LeTx.
Hemodynamic Measurements. Compared to animals challenged with diluent, LPS without norepinephrine decreased MBP throughout. These decreases were statistically significant over the early time period (p ϭ 0.04 for the differences comparing LPS alone and diluent), and the magnitude of these differences varied with time over both periods (p ϭ 0.003 and Ͻ0.001, respectively, for the interaction with time) (Fig. 3A) . Compared with diluent animals, LeTx alone was not statistically different during the early period and had variable effects on MBP (p Ͻ 0.001 for the interaction with time) (Fig. 3B ). However, during the late period, LeTx decreased MBP significantly throughout (p Ͻ 0.001 for the differences comparing LeTx alone and diluent), and the magnitude of these effects varied with time (p Ͻ 0.001 for the interaction with time). Compared to toxin challenge alone, early norepinephrine treatment increased MBP with both toxins, but this effect was only significant with LeTx (p Ͻ 0.001) (Fig. 3, C and D) . With both toxins, the early increase with norepinephrine continued into the later time period but did not persist and was not statistically significant.
Compared to animals challenged with diluent, LPS alone increased HR early and decreased it late (p Ͻ 0.001 for differences between LPS alone and diluent over both periods) (Fig. 4A) . Reductions in HR with LPS later were greater with time (p Ͻ 0.001 for interaction with time). Early, LeTx alone had variable effects on HR (p Ͻ 0.001 for the interaction with time) (Fig. 4B) . Late, LeTx decreased HR throughout (p Ͻ 0.001 for the differences between LeTx alone and diluent), but these decreases varied over time (p Ͻ 0.001 for the interaction with time). Compared with LPS alone, treatment with norepinephrine did not alter HR significantly, early or late, but over the 24 hours was associated with progressive increases in a trend approaching significance (p ϭ 0.10) (Fig. 4C ). With LeTx, norepinephrine did not alter HR significantly early or late (Fig. 4D) .
Arterial Blood Gas and Lactate Measurements. Compared with diluent chal- lenge, LPS alone decreased arterial pH and base excess, and increased lactate (p Ͻ 0.001 for the differences comparing LPS alone and diluent), but these changes were greater at later time points (p Ͻ 0.001 for the interaction with time) (Fig. 5 ). Compared with diluent, LeTx decreased arterial pH and base excess sig-nificantly (p Ͻ 0.001 and p ϭ 0.002, respectively, for the differences comparing LeTx alone and diluent). Norepinephrine with LPS challenge significantly increased arterial pH and base excess, and decreased lactate compared with LPS alone (p Յ 0.04 for all differences comparing LPS with norepinephrine to LPS alone), and changes in pH were greater at later time points (p ϭ 0.04 for the interaction with time). Compared to LeTx challenge alone, treatment with norepinephrine did not alter arterial pH, base excess, or lactate significantly throughout.
Plasma Catecholamines, NO, Cytokine, and SOD Measurements. Compared to animals challenged with diluent only, LPS increased plasma catecholamine (norepinephrine and epinephrine) and NO levels across the 4-and 8-hour measurement times (p Ͻ 0.001 for each) (Fig.  6) . LPS also increased cytokine levels significantly at these time points (p Յ 0.05 for all except IL-1␤ and tumor necrosis factor-alpha at 4 hours, data not shown). LeTx did not cause significant changes in any of these parameters throughout. Compared to animals challenged with diluent only, with the exception of lung SOD measures that were decreased with LeTx challenge at 8 hours (p ϭ 0.02), no other SOD measure was altered significantly with either toxin during the study (data not shown).
DISCUSSION
Although norepinephrine treatment increased blood pressure significantly before the onset of lethality with LeTx, it did not improve survival. In contrast, early increases in blood pressure with norepinephrine in LPS-challenged animals, although not reaching significance, were associated with beneficial survival effects. These and other findings suggest that the relationship among hypotension, tissue hypoperfusion, and lethality for LPS and LeTx may differ.
As observed in this model, LPS is known to increase NO and inflammatory cytokine levels, both of which are associated with arterial dilation and myocardial dysfunction (25) (26) (27) (28) . These same mediators have also been implicated in loss of responsiveness to the vasopressor effects of endogenous catecholamines (29, 30) . Together, these abnormalities contribute to the tissue hypoperfusion and injury leading to lethality with LPS (23, 30) . Possibly as a compensatory response, endogenous epinephrine and norepinephrine levels were increased with LPS in this study. Although hypotension with LPS may have been reduced because of hourly fluid administration (i.e., 4 mL/ kg/hr during toxin and treatment administration), metabolic acidosis and increased lactate levels were prominent in LPS-challenged animals. Although this acidosis may be due in part to a direct effect of LPS on mitochondrial function, it likely also reflects tissue hypoperfusion. Under these circumstances, norepinephrine's vasoconstrictive and inotropic effects would likely have benefit. Both of these effects can improve tissue perfusion and are a basis for norepinephrine's use during shock related to the systemic inflammatory response during sepsis (31, 32) . In keeping with these actions, norepinephrine during LPS challenge was associated with decreased acidosis and lactate levels, and improved survival. Gradual increases in HR with norepinephrine in LPS-challenged animals suggest that chronotropic effects may have also contributed to its beneficial effects. Finally, norepinephrine may have antiinflammatory effects through the beta-2 receptor which could also be beneficial with LPS challenge (33) .
In contrast to LPS, hypotension and lethality with LeTx challenge were not associated with increases in NO, inflammatory cytokine, or endogenous catecholamine levels. Furthermore, evidence of metabolic acidosis with lactate increases was small with LeTx compared with LPS. Finally and most noticeably, although norepinephrine increased blood pressure with LeTx, it did not alter survival or acid-base parameters. These findings collectively raise the possibility that in contrast to LPS, hypotension with LeTx in this model may be a secondary phenomenon and not a primary cause of lethality. Instead, LeTx may have produced direct cellular injury leading to lethality through mechanisms insensitive to increases in blood pressure or tissue perfusion with norepinephrine. The downstream mitogen-activated protein kinases inhibited after LF cleavage of MKKs include p38 (␣, ␤, ␥, and ␦), extracellular-signal-regulated kinases 1 and 2, and c-Jun N-terminal kinases 1, 2, and 3. These molecules control a wide range of critical cellular functions (34) . In addition to effects on host defense, inhibition of these pathways by LF has been shown to cause apoptosis of macrophage and endothelial cells, and disruption of endothelial and neutrophil cytoskeleton function (14 -16, 35, 36) . Genomic and proteomic analysis and direct in vitro studies have also suggested that LeTx may alter energy metabolism and impair mitochondrial function (37) (38) (39) . Such changes might secondarily alter vascular integrity or myocardial function and cause hypo- tension, the reversal of which would not alter outcome.
It is also possible, however, that increased blood pressure with norepinephrine during LeTx challenge had maladaptive effects that negated its beneficial ones. Notably, if LeTx caused myocardial dysfunction out of proportion to injury to the peripheral vasculature, the vasopressor effects of norepinephrine might have increased afterload and worsened cardiac output. LeTx has been reported to alter myocardial function (40) . However, this study is difficult to interpret because the bolus administration of toxin in animals resulted in profound reductions in systemic blood pressures over very rapid periods, as has been seen in similar models (40, 41) . Increased afterload resulting in impaired cardiac output with norepinephrine in the current study might have also been expected to produce more severe tissue acidosis.
Absence of a beneficial survival effect of norepinephrine with LeTx does not seem to be related to the treatment doses that were studied. The intermediate dose protective with LPS is comparable to a norepinephrine dose of 20 g/min in a 70-kg human. This dose is frequently used clinically during severe sepsis as well as in LPS-challenged rat models (42, 43) . Furthermore, neither increasing nor decreasing the norepinephrine dose administered resulted in improved survival with LeTx. Whether the titration of norepinephrine based on hemodynamic measures during LeTx infusion or the use of alternate vasopressors or agents with greater inotropic effects would have beneficial effects with LeTx requires further study. Finally, although fluid administration in volumes (10 and 20 mL/kg/hr) greater than that used in the current study worsened outcome with LeTx in this rat model, it is possible that norepinephrine in combination with these higher fluid amounts would have had benefit (19) . Studies to examine this possibility would ideally use measures of preload to adjust fluids and measures of perfusion to titrate norepinephrine as is done clinically. However, such studies may only be possible in a large animal model.
Although LeTx is important in the pathogenesis of B. anthracis, other products likely contribute as well. Recent in vivo studies have shown that edema toxin may have a substantial role in the shock and lethality associated with anthrax (19, 44) . Cell wall components from anth-rax may also contribute to shock (45) . Whether hemodynamic dysfunction related to these other mediators will be more responsive to conventional hemodynamic support than LeTx in the current study requires investigation. On the one hand, edema toxin is an adenyl cyclase that has the potential to actually negate the vasopressor effects of agents like norepinephrine (46) . On the other hand, if cell wall plays a role in the shock caused by anthrax, it likely does so through some of the same inflammatory response pathways LPS does (45) . In this case, fluid and vasopressors might have beneficial effects.
The present findings should not be interpreted to suggest that patients presenting with suspected anthrax infection and shock not receive aggressive hemodynamic support to maintain blood pressure and organ perfusion. Such therapies are necessary regardless of the underlying etiological agent. These findings do suggest, however, that normalization of blood pressure with pressor agents may mask ongoing cellular injury related to LeTx.
This study has several limitations. As earlier noted, norepinephrine was not titrated in individual animals, and direct measures of myocardial function were not performed. Further, this study neither includes mechanical ventilation which would typically be applied to a critically ill patient nor did it examine the effects of vasopressor therapy in combination with a toxin-directed agent. Therefore, whether the findings from this small animal model can be extrapolated clinically is not clear. Regarding a methodologic point, although it would have been ideal to have randomized an independent control group (i.e., diluent challenged) for these experiments, the use of such animals could not be justified because a similarly treated group was undergoing concurrent study in another protocol.
Both in this study and an earlier one, treatment with fluid or norepinephrine, although beneficial with LPS or bacteria challenge, was either not effective or actually worsened outcome in animals challenged with LeTx (19) . Whether these findings relate to the extremely poor outcome (e.g., 100% lethality) in patients with shock receiving conventional hemodynamic support during the 2001 United States anthrax outbreak is unclear. They do, however, emphasize the need to better define the pathogenic mechanisms leading to death with anthrax and the effectiveness of conventional treatments.
